NCT05620342View on ClinicalTrials.gov

Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 21, 2023

Primary Completion Date

November 24, 2027

Study Completion Date

October 24, 2029

Conditions
Lung CancerSmall Cell Lung CarcinomaNon Small Cell Lung Cancer
Interventions
BIOLOGICAL

iC9.GD2.CAR.IL-15 T Infusion

iC9-GD2.CAR.IL-15 T-cells product will be administered via intravenous injection over 5 - 10 minutes.

Trial Locations (1)

27514

RECRUITING

Lineberger Comprehensive Cancer Center, Chapel Hill

Sponsors

Collaborators (1)

Bellicum Pharmaceuticals
All Listed Sponsors
collaborator

Bellicum Pharmaceuticals

INDUSTRY

collaborator

United States Department of Defense

FED

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT05620342 - Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer | Biotech Hunter | Biotech Hunter